دورية أكاديمية
أعرض في EDS

Prevalence of Polypharmacy in Patients With Vestibular and Balance Complaints.

التفاصيل البيبلوغرافية
العنوان: Prevalence of Polypharmacy in Patients With Vestibular and Balance Complaints.
المؤلفون: Jeong SS; Department of Otolaryngology; Medical University of South Carolina, Charleston, South Carolina, USA.; Department of Otolaryngology, Albert Einstein College of Medicine, Bronx, New York, USA., Chen T; Department of Otolaryngology; Medical University of South Carolina, Charleston, South Carolina, USA., Timor TA; Department of Pharmacy Services; Medical University of South Carolina, Charleston, South Carolina, USA., Busch AL; Department of Pharmacy Services; Gulf Coast Veteran's Health Care System, Pensacola, Florida, USA., Meyer TA; Department of Otolaryngology; Medical University of South Carolina, Charleston, South Carolina, USA., Nguyen SA; Department of Otolaryngology; Medical University of South Carolina, Charleston, South Carolina, USA., Rizk HG; Department of Otolaryngology; Medical University of South Carolina, Charleston, South Carolina, USA.
المصدر: Ear and hearing [Ear Hear] 2023 May-Jun 01; Vol. 44 (3), pp. 506-517. Date of Electronic Publication: 2022 Nov 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Williams And Wilkins Country of Publication: United States NLM ID: 8005585 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4667 (Electronic) Linking ISSN: 01960202 NLM ISO Abbreviation: Ear Hear Subsets: MEDLINE
أسماء مطبوعة: Publication: Baltimore Md : Williams And Wilkins
Original Publication: Baltimore, Williams & Wilkins.
مواضيع طبية MeSH: Dizziness*/chemically induced , Dizziness*/epidemiology , Dizziness*/diagnosis , Polypharmacy*, Humans ; Retrospective Studies ; Prevalence ; Cross-Sectional Studies ; Vertigo/diagnosis
مستخلص: Objectives: To determine the prevalence of polypharmacy in patients presenting with dizziness to a tertiary neurotology clinic and analyze the association between polypharmacy and clinical characteristics.
Design: Retrospective, cross-sectional review. Demographics, symptoms, diagnoses, medications, audiometry, dizziness handicap index (DHI) scores, and cognitive failure questionnaire (CFQ) scores were extracted from charts of patients seen as new patients from September 1, 2019, to March 31, 2020, with a primary complaint of dizziness.
Results: A total of 382 patients were included. More than two-thirds of the patients (n = 265, 69.4%) met criteria for polypharmacy (≥5 medications), of which most (n = 249, 94.0%) were prescribed a potentially ototoxic drug. Approximately 10% of patients were taking five or more ototoxic medications (oto-polypharmacy). Polypharmacy was correlated to age and was more common for patients with diabetes, hypertension, other cardiovascular comorbidities, and depression (odds ratio [OR], 3.73-6.67; p < 0.05). Polypharmacy was twice as likely in patients with mild to moderate hearing loss (OR 2.02 [1.24-3.29] and OR 2.13 [1.06-4.27], respectively; p < 0.05) and ~1.5× more likely in patients who had moderate to severe DHI scores (OR 1.65 [1.05-2.59] and OR 1.63 [1.00-2.65], respectively; p < 0.05). Patients with polypharmacy also had higher CFQ scores compared to those without polypharmacy (CFQ 32.5 [19.0-48.0] versus CFQ 25.0 [13.0-40.0]; p = 0.002. Oto-polypharmacy was more common for patients with lightheadedness as a dizziness descriptor (OR 3.16 [1.56-6.41]; p < 0.01). However, oto-polypharmacy was only more common for patients with mild to moderate hearing loss (OR 2.69 [1.33-5.45] and OR 2.86 [1.31-6.20], respectively; p < 0.01) and severe DHI scores (2.31 [1.12-4.77], p = 0.02).
Conclusions: The prevalence of polypharmacy in patients with vestibular disorders is high. Some of the medications that patients are on are also potentially ototoxic at variable degrees. Polypharmacy is more common when lightheadedness is one of the dizziness descriptors and seems to be associated with worse scores on patient-reported outcome measures (DHI, CFQ). Medication reconciliation and multidisciplinary involvement could help to better address polypharmacy in this patient population. However, further investigation is needed to elucidate polypharmacy's role in symptom presentation, vestibular testing results, and therapeutic strategies.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Avery A. J., Ghaleb M., Barber N., Dean Franklin B., Armstrong S. J., Serumaga B., Dhillon S., Freyer A., Howard R., Talabi O., Mehta R. L. (2013). The prevalence and nature of prescribing and monitoring errors in English general practice: A retrospective case note review. Br J Gen Pract, 63, e543–553.
Barnett N. L., Oboh L., Smith K. (2016). Patient-centred management of polypharmacy: A process for practice. Eur J Hos Pharm, 23, 113–117.
Basura G. J., Adams M. E., Monfared A., Schwartz S. R., Antonelli P. J., Burkard R., Bush M. L., Bykowski J., Colandrea M., Derebery J., Kelly E. A., Kerber K. A., Koopman C. F., Kuch A. A., Marcolini E., McKinnon B. J., Ruckenstein M. J., Valenzuela C. V., Vosooney A., Walsh S. A., et al. (2020). Clinical practice guideline: Ménière’s disease. Otolaryngol Head Neck Surg, 162(2_Suppl), S1–S55.
Becerra-Camargo J., Martinez-Martinez F., Garcia-Jimenez E. (2013). A multicentre, double-blind, randomised, controlled, parallel-group study of the effectiveness of a pharmacist-acquired medication history in an emergency department. BMC Health Serv Res, 13, 337.
Besser J., Stropahl M., Urry E., Launer S. (2018). Comorbidities of hearing loss and the implications of multimorbidity for audiological care. Hear Res, 369, 3–14.
Best C., Eckhardt-Henn A., Tschan R., Dieterich M. (2009). Psychiatric morbidity and comorbidity in different vestibular vertigo syndromes. Results of a prospective longitudinal study over one year. J Neurol, 256, 58–65.
Byun Y. J., Levy D. A., Nguyen S. A., Brennan E., Rizk H. G. (2021). Treatment of vestibular migraine: A systematic review and meta-analysis. Laryngoscope, 131, 186–194.
Chimirri S., Aiello R., Mazzitello C., Mumoli L., Palleria C., Altomonte M., Citraro R., De Sarro G. (2013). Vertigo/dizziness as a Drugs’ adverse reaction. J Pharmacol Pharmacother, 4(Suppl 1), S104–S109.
Chumney E. C., Robinson L. C. (2006). The effects of pharmacist interventions on patients with polypharmacy. Pharm Pract (Granada), 4, 103–109.
Felton M., Hanlon J. T., Perera S., Thorpe J. M., Marcum Z. A. (2015). Racial differences in anticholinergic use among community-dwelling elders. Consult Pharm J Am Soc Consult Pharm, 30, 240–245.
Gu Q., Dillon C. F., Burt V. L. (2010). Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief, 42, 1–8.
Guerra-Jiménez G., Arenas Rodríguez A., Falcón González J. C., Pérez Plasencia D., Ramos Macías Á. (2017). Epidemiology of vestibular disorders in the otoneurology unit. Acta Otorrinolaringol Esp (Engl Ed), 68, 317–322.
Halli-Tierney A. D., Scarbrough C., Carroll D. (2019). Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician, 100, 32–38.
Kanzaki J., Goto F. (2015). Psychiatric disorders in patients with dizziness and Ménière’s disease. Acta Otolaryngol, 135, 447–450.
Khezrian M., McNeil C. J., Murray A. D., Myint P. K. (2020). An overview of prevalence, determinants and health outcomes of polypharmacy. Therapeutic Advances in Drug Safety, 11, 2042098620933741.
Kini V., Ho P. M. (2018). Interventions to improve medication adherence: A review. JAMA, 320, 2461–2473.
Lahmann C., Henningsen P., Brandt T., Strupp M., Jahn K., Dieterich M., Eckhardt-Henn A., Feuerecker R., Dinkel A., Schmid G. (2015). Psychiatric comorbidity and psychosocial impairment among patients with vertigo and dizziness. J Neurol Neurosurg Psychiatry, 86, 302–308.
Lauritsen C. G., Marmura M. J. (2017). Current treatment options: Vestibular migraine. Curr Treat Options Neurol, 19, 38.
Liu F., Ma T., Che X., Wang Q., Yu S. (2017). The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol, 8, 524–524.
Liu Y. F., Locklear T. D., Sharon J. D., Lacroix E., Nguyen S. A., Rizk H. G. (2019). Quantification of cognitive dysfunction in dizzy patients using the neuropsychological vertigo inventory. Otol Neurotol, 40, e723–e731.
Lotfaliany M., Bowe S. J., Kowal P., Orellana L., Berk M., Mohebbi M. (2018). Depression and chronic diseases: Co-occurrence and communality of risk factors. J Affect Disord, 241, 461–468.
Maher R. L., Hanlon J., Hajjar E. R. (2014). Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf, 13, 57–65.
Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatr, 17, 230.
McClure J. A., Lycett P., Baskerville J. C. (1982). Diazepam as an anti-motion sickness drug. J Otolaryngol, 11, 253–259.
Mekonnen A. B., McLachlan A. J., Brien J. A. (2016). Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: A systematic review and meta-analysis. BMJ Open, 6, e010003.
Molokhia M., Majeed A. (2017). Current and future perspectives on the management of polypharmacy. BMC Fam Pract, 18, 70.
O’Mahony D., O’Sullivan D., Byrne S., O’Connor M. N., Ryan C., Gallagher P. (2014). STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing, 44, 213–218.
Patel E., Pevnick J. M., Kennelty K. A. (2019). Pharmacists and medication reconciliation: A review of recent literature. Integr Pharm Res Pract, 8, 39–45.
Patel J. J., Levy D. A., Nguyen S. A., Rizk H. G., Meyer T. A. (2020). Depression in Ménière’s disease: A systematic review and meta-analysis. J Laryngol Otol, 134, 293–301.
Popkirov S., Stone J., Holle-Lee D. (2018). Treatment of persistent postural-perceptual dizziness (PPPD) and related disorders. Curr Treat Options Neurol, 20, 50.
Reeve E., Shakib S., Hendrix I., Roberts M. S., Wiese M. D. (2014). Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol, 78, 738–747.
Rizk H. G., Sharon J. D., Lee J. A., Thomas C., Nguyen S. A., Meyer T. A. (2020a). Cross-sectional analysis of cognitive dysfunction in patients with vestibular disorders. Ear Hear, 41, 1020–1027.
Rizk H. G., Lee J. A., Liu Y. F., Endriukaitis L., Isaac J. L., Bullington W. M. (2020b). Drug-induced ototoxicity: A comprehensive review and reference guide. Pharmacotherapy, 40, 1265–1275.
Roberts R. A., Jacobson G. P., Hatton K. (2020). Multiple co-occurring vestibular disorders identified using the dizziness symptom profile. Am J Audiol, 29, 410–418.
Scott I., Anderson K., Freeman C. (2017). Review of structured guides for deprescribing. Eur J Hosp Pharm, 24, 51–57.
Shen Y., Qi X., Wan T. (2020). The treatment of vestibular migraine: A narrative review. Ann Indian Acad Neurol, 23, 602–607.
Tisdale J. E. (2010). Drug-induced diseases: prevention, detection, and management. ASHP. ashp.org/-/media/store-files/p2050-frontmatter.
Varkey P., Cunningham J., Bisping D. S. (2007). Improving medication reconciliation in the outpatient setting. Jt Comm J Qual Patient Saf, 33, 286–292.
Verdoorn S., Kwint H. F., Blom J. W., Gussekloo J., Bouvy M. L. (2019). Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study). PLoS Med, 16, e1002798.
تواريخ الأحداث: Date Created: 20221115 Date Completed: 20230417 Latest Revision: 20230531
رمز التحديث: 20230531
DOI: 10.1097/AUD.0000000000001292
PMID: 36377041
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-4667
DOI:10.1097/AUD.0000000000001292